How did ANGO's Q2 2025 EPS surprise impact its stock?

ANGO's Q2 2025 EPS surprise had a positive impact on its stock, contributing to a 38.0% increase in share price following the earnings release. Here's a detailed analysis: 1. **EPS Surprise and Stock Price Reaction**: AngioDynamics reported an EPS of $-0.04 for Q2 2025, surpassing the Zacks Consensus Estimate of a loss of $0.13 per share. This positive surprise led to a significant uptick in the stock price. The company has consistently exceeded EPS estimates, with this being the fourth such occurrence. 2. **Investor Confidence and Market Sentiment**: The earnings beat reinforced investor confidence, as evidenced by a 38.0% increase in the stock price following the earnings release. This indicates that investors were pleased with the company's performance and outlook. 3. **Analyst Expectations and Stock Performance**: Analysts had expected a more significant loss of $0.11 per share in Q2 2025. The actual EPS of $-0.04 was much better than anticipated, contributing to the positive stock price movement. This discrepancy between expected and actual EPS figures often leads to a positive price reaction as investors revise their estimates upward. 4. **Guidance and Future Prospects**: AngioDynamics provided optimistic guidance for fiscal 2025, expecting revenue to be in the range of $285 million to $288 million. This positive outlook, coupled with the earnings beat, likely bolstered investor confidence in the company's future performance, further supporting the stock price increase. In conclusion, ANGO's Q2 2025 EPS surprise of $0.07 per share above expectations, combined with positive guidance, significantly boosted investor confidence and contributed to a 38.0% increase in the stock price following the earnings release.